A mosquito-borne viral infection spreading in the Americas and Europe, caused by the chikungunya virus (CHIKV), a Togaviridae virus transmitted by Aedes mosquitoes. As of 2017, there have been more than one million reported cases in the Americas and the economic impact is significant (e.g. Colombia outbreak 2014: $73.6m1).
- VLA1553 is a monovalent, single dose, live-attenuated vaccine candidate against chikungunya.
- VLA1553 was granted Fast Track designation by the FDA in December 20181 and a Phase 1 clinical study is currently ongoing.
Additional information about chikungunya: